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H2 blockers increase incidence of docetaxel-induced skin toxicity 
 
Part of this study was presented as a poster discussion in the “Patient Care: Cancer-Related 
Complications” session (abstract number 9536) at the 2009 Annual Meeting of the American Society of 
Clinical Oncology. 
 





































































Steroids and H2 blockers are commonly used as supportive care for taxane-containing chemotherapy, but 
they also affect docetaxel’s primary metabolizer, cytochrome P450 3A4. This retrospective observational 
study was performed to better understand the effects of these compounds on docetaxel-induced skin 
toxicities, specifically hand-foot syndrome (HFS) and facial erythema (FE), a relationship that is currently 
poorly understood. 
Patients and methods 
Member institutions of the Japan Breast Cancer Research Group were invited to complete a questionnaire 
on the occurrence of grade 2 or higher HFS and FE among patients treated between April 2007 and 
March 2008 with docetaxel as an adjuvant or neoadjuvant chemotherapeutic treatment for breast cancer.  
Results 
We obtained data for 993 patients from 20 institutions. Twenty percent received H2 blockers, and all 
patients received dexamethasone. Univariate and multivariate analyses revealed that H2 blockers are 
associated with a significantly higher incidence of both HFS and FE. The incidence of FE was 
significantly higher for the docetaxel + cyclophosphamide (TC) regimen than for non-TC regimens 




































































Use of H2 blockers as premedication in breast cancer patients receiving docetaxel significantly increases 
the risk of both HFS and FE. 
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Docetaxel is one of the most active chemotherapeutic agents against breast cancer [1]. Data 
from a randomized trial show an increased tumor response with increasing docetaxel dose within a dose 
range of 60–100 mg/m2 administered every 3 weeks [1]. In general, the incidence and severity of adverse 
events increases with docetaxel dose. Previously, docetaxel dose was limited by hematologic toxicities 
such as febrile neutropenia [2]; however, their impact has been drastically reduced by the use of 
granulocyte colony-stimulating factor (GCSF) as prophylaxis. Thus, in recent years, non-hematologic 
toxicities have become more clinically important. The incidence and severity of a number of 
non-hematologic toxicities, such as fluid retention (FR), are associated with increasing docetaxel dose [1]. 
In our own clinical practice, we have recently experienced many cases of docetaxel-induced hand-foot 
syndrome (HFS) and facial (cheek) erythema (FE), especially among patients receiving relatively high 
doses of docetaxel for adjuvant and neoadjuvant chemotherapy. 
 Corticosteroids administered over 3 days, starting 2 days prior to chemotherapy, have been 
shown to delay the onset of docetaxel-induced FR. In one study, patients who received 
methylprednisolone premedication had significantly delayed onset of FR. and received a significantly 



































































(docetaxel, doxorubicin, cyclophosphamide) and given corticosteroid premedication (starting 1 day prior 
to chemotherapy), Suh et al. [4] found that corticosteroid postmedication (three 8 mg doses, b.i.d., until 1 
day after chemotherapy) yielded no improvement in the incidence of severe FR on day 2. 
Both docetaxel-induced cumulative FR and the means by which corticosteroids delay its onset 
remain poorly understood. One possible explanation involves induction of the cytochrome P450 (CYP) 
system. Clinically relevant doses of dexamethasone (e.g. 8 mg orally two times a day for 5 days), 
reportedly increase hepatic cytochrome P450 3A4 (CYP3A4) activity by an average of 25.7% [5]. Thus, 
dexamethasone treatment could potentially bring about a clinically significant increase in the clearance of 
CYP3A4 substrates such as docetaxel.  
 H2 blockers, such as cimetidine and ranitidine, are weak inhibitors of CYP3A4 [6]. A single 
dose of cimetidine (800 mg orally) was found to have a small but significant effect (30% increase) on the 
area under the concentration–time curve (AUC) of midazolam. Five days of cimetidine treatment (400 mg 
orally b.i.d.) increased the AUC of epirubicin by 50% (not statistically significant due to a small sample 
size) [7]. Cimetidine also reportedly affects the pharmacokinetics of 5-fluorouracil (5-FU): pretreatment 
with cimetidine for 4 weeks led to an increased 5-FU plasma concentration and AUC [8]. For oral 5-FU, 
the AUC was increased by 72% and for intravenous 5-FU, the AUC was increased by 27% and total body 
clearance was decreased by 28% [8]. 



































































in Japan, probably as a result of the common practice of administering H2 blocker premedication for 
paclitaxel treatment. Another possible explanation is that clinicians are aiming to minimize the 
gastrointestinal side effects of dexamethasone, although there is no convincing evidence to support this 
usage [9].We hypothesized that H2 blockers would increase the incidence of docetaxel-induced skin 
toxicity, given their inhibitory effect on the enzymes that metabolize docetaxel. We also hypothesized that 
use of steroids prior to chemotherapy would decrease the incidence of these toxicities via the reverse 
action. In the present retrospective observational study, we aimed to gather data to investigate these 
hypotheses. 
 
PATIENTS AND METHODS 
 
Nearly 100 institutions belonging to the Japan Breast Cancer Research Group were invited to 
complete a questionnaire, asking them to use existing medical records to retrospectively investigate the 
occurrence of grade 2 or higher HFS and FE among patients treated between April 2007 and March 2008 
with docetaxel as an adjuvant or neoadjuvant chemotherapeutic treatment for breast cancer. Twenty of 
these institutions returned data on patients. We asked that cases of HFS and FE be classified in 
accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events 



































































The following data were collected on a per-institution basis: (1) docetaxel dose; (2) 
chemotherapeutic agents concurrently administered; (3) whether steroids or H2 blockers were used; (4) 
occurrence of grade 2 or higher HFS or FE. Furthermore, we also ascertained the standard doses and 
regimens for steroids and H2 blockers used by each institution (i.e. data on doses and regimens for 
docetaxel, steroids and H2 blockers was based on institutional policy rather than individual patients’ 
records). 
Statistical analyses were performed using the chi-squared test and multivariate logistic 
regression. 
This observational study using only the existing medical records was approved by the Ethics 
Committee of Kyoto University Graduate School of Medicine, and performed according to the 
Declaration of Helsinki and the Ethical Guidelines for Epidemiological Research of the Ministry of 
Education, Culture, Sports, Science, and Technology and the Ministry of Health, Labour, and Welfare of 
Japan. Although informed consent from patients is not a formal requirement for a study of this type (as 
per the above-mentioned guidelines), each subject was publicly provided with the opportunity to opt out 








































































Of the nearly 100 institutions that were invited to participate, questionnaires were returned by 
22, of which two institutions had no eligible patients, leaving 20 institutions that returned data. Data on 
993 patients was available. Details of the drugs received by the 993 patients are provided in Table 1. 
The chemotherapeutic regimens used were as follows: docetaxel monotherapy (T), docetaxel + 
cyclophosphamide (TC), docetaxel + capecitabine (TX), and docetaxel + trastuzumab (TH). A total of 
760 (76.5%) patients received docetaxel at a dose of 75 mg/m2, and 852 patients were treated with 
docetaxel monotherapy. H2 blockers were administered to about 20% of patients. Three H2 blockers, 
ranitidine, famotidine and lafutidine, were used. Dexamethasone was the only steroid administered, and 
all patients in the present study received dexamethasone. The dose of dexamethasone used on days 1 and 
2 varied, depending on the chemotherapeutic regimen used and institutional preference, but 8 mg was the 
most commonly used dose on both days. 
 
Univariate analysis of factors affecting skin toxicity incidence 
 Table 2 shows the relationship between the incidence of HFS and FE and the institutional 
policy with respect to H2 blockers, steroids and chemotherapeutic regimen. HFS and FE occurred in 



































































between the TC regimen and other regimens combined (FE: odds ratio [OR] 2.73, P = 0.010; HFS: OR 
0.58, P = 0.245). Given that the TX regimen was used in a very small number of patients (less than 5%), 
we did not compare the incidence of HFS and FE in this group with that of other regimens, particularly 
given that the TX regimen is already known to be associated with a higher incidence of HFS [10,11]. Use 
of H2 blockers significantly increased the incidence of both HFS (OR 2.55, P < 0.001) and FE (OR 3.00, 
P < 0.001). Lafutidine was associated with a significantly higher OR than the other two H2 blockers for 
both HFS (OR 11.73, P < 0.001) and FE (OR 18.48, P < 0.001). There was no general relationship 
between the dose of steroid on day 1 and/or day 2 and the incidence of either HFS or FE, although there 
was a small but significantly higher incidence of FE among patients receiving >8 mg of dexamethasone 
on day 1 compared with those who received ≤8 mg (OR 1.80, P = 0.006). 
 
Cumulative incidence of HFS and FE 
The cumulative incidences of HFS and FE are depicted in Figure 1. Given that most adjuvant 
and neo-adjuvant docetaxel-based chemotherapy regimens involve four cycles, we investigated 
cumulative toxicity for cycles 1 and 2, and cycles 3 and after. Grade 2 or higher HFS occurred in 5% of 
patients in cycle 1, and increased as chemotherapy continued. When an H2 blocker was used, 20% of 
patients developed grade 2 or higher HFS by cycles 3 and after. The cumulative incidence of HFS in the 



































































The incidence of FE was also affected by the use of an H2 blocker. In the absence of an H2 
blocker, the cumulative incidence of FE by cycles 3 and after was less than a quarter of that seen when an 
H2 blocker was used. 
 
Multivariate analysis of factors affecting skin toxicity incidence 
Tables 3 and 4 show the relationships between steroid (day 1: Table 3; day 2: Table 4) and H2 
blocker institutional policies, chemotherapy regimen and HFS and FE incidence as determined by 
multivariate logistic regression analysis. Use of a steroid on days 1 and 2 was a confounding factor, so we 
performed separate analysis for patients who used steroids on these days. 
  The two multivariate logistic regression analyses show that use of H2 blockers significantly 
increased the incidence of HFS and FE. Lafutidine had the strongest influence on the incidence of both 
HFS and FE. Ranitidine seemed to have the least influence, although there was still a significant increase 
in the incidence of FE (OR 2.58; P = 0.029) with day 2 steroid use, and a non-significant increase in FE 
incidence with day 1 steroid use (OR 2.17; P = 0.101) 
Both multivariate analyses showed that the TC regimen was associated with a significantly 
increased risk of FE but not HFS relative to the other regimens combined. There was no relationship 
between the dose of dexamethasone given as premedication on day 1 or after chemotherapy on day 2 and 





































































This was a retrospective multi-institutional observational study designed to investigate the 
correlation between docetaxel-induced skin toxicity and the use of steroids and/or H2 blockers. We found 
that H2 blockers, especially lafutidine, significantly increased the incidence of HFS and FE. The dose of 
dexamethasone, given either as premedication on day 1 or after chemotherapy on day 2, did not affect the 
incidence of either HFS or FE. We also found that the TC regimen is associated with a significantly 
higher risk of FE but not HFS relative to other regimens. 
 The major limitations of our study are, first, that this is a retrospective analysis, with all the 
associated drawbacks. Second, the doses and regimens of steroids and H2 blockers used in our analysis are 
based on institutional policies rather than individual patients’ data. Although we found that lafutidine was 
associated with a significantly higher incidence of HFS and FE, only one institution used lafutidine, so 
observer bias may have contributed to this outcome. A further drawback is that pharmacokinetic data 
from the patients were not available. The best study design to answer the question of whether H2 blockers 
increase the incidence of skin toxicity due to increased docetaxel AUC would be a randomized controlled 
trial, comparing docetaxel with or without H2 blockers, with HFS and FE incidences as endpoints, and 
including an analysis of docetaxel pharmacokinetics. However, it would not only be prohibitively 



































































would place them at risk of an adverse outcome in the absence of apparent clinical benefit. 
In vitro studies indicate that CYP3A4 is the major enzyme involved in docetaxel metabolism 
[12]. Less than 10% of unmetabolized docetaxel is excreted into the feces, and total urinary excretion is 
also less than 10% [13]. Total activity of enzymes in the CYP3A family has been identified as a strong 
predictor of docetaxel clearance and most likely accounts to a large extent for the observed 
inter-individual variability in drug clearance and plasma concentration AUC. Although the fact that 
docetaxel is predominantly metabolized by CYP3A makes the agent subject to a host of enzyme-mediated 
drug interactions, little data is available on potential interactions in humans [14]. CYP3A expression 
varies as much as 40-fold between individuals, which may be due to factors including genetic mutations 
and up- or down-regulation by environmental stimuli [15]. In fact, there is a wide overlap in the AUC 
values of patients receiving different doses of docetaxel (e.g. 75 and 100 mg/m2), in spite of drug dose 
being calculated on the basis of body surface area [16], which could be explained by a drug–environment 
interaction. 
A decrease in total body clearance and an increase in the AUC of docetaxel is associated with 
increased frequency and severity of side effects [17]. The AUC of docetaxel is reportedly a significant 
predictor of severe neutropenia, with a 50% decrease in docetaxel clearance corresponding to a 4.3-fold 
increase in the risk of grade 4 neutropenia and a 3.0-fold increase in the risk of febrile neutropenia [17]. 



































































compliance and the dose intensity of chemotherapy, both of which might lower the efficacy of treatment. 
A recent study has indicated that skin toxicity occurs in 53% of patients and nail toxicity occurs in 51% of 
patients receiving docetaxel [18]. Battegay [19] suggested that the antiangiogenic properties of taxanes 
may be involved in the pathogenesis of nail toxicity. Wasner et al. [20] suggested the existence of a 
neurogenically mediated inflammatory process. However, little is known about the mechanism underlying 
drug-induced HFS and FE, except that the two conditions seem to be dose related. In a Japanese study 
involving a low dose of docetaxel (60 mg/m2), there was a generally low incidence HFS and FE [21]. 
In order to decrease the incidence of docetaxel toxicity, especially FR, dexamethasone (8 mg 
orally b.i.d. for 3 consecutive days starting 24 hours before docetaxel infusion) is often used. This seems 
to be effective for reducing the incidence and severity of FR [22], but the effect on skin toxicity is not 
well understood. In our analysis, the dose of steroid on either day 1 or day 2 had little impact on the 
incidence of grade 2 or higher HFS and FE. Since most institutions included in this study start 
dexamethasone therapy just prior to chemotherapy infusion, we were unable to determine whether 
dexamethasone given the day before chemotherapy has any effect on the incidence of skin toxicity. Since 
dexamethasone at doses used clinically increases CYP3A4 activity (with extensive inter-subject 
variability) [5], an increase in docetaxel clearance might be a factor explaining the lower incidence of FR, 
although this hypothesis requires confirmation by a well-designed clinical pharmacology study.  



































































administration of H1 receptor antagonists plus H2 receptor antagonists 30 minutes prior to paclitaxel 
infusion [23], an approach that has become the standard premedication for paclitaxel administration. 
Although H1 and H2 receptor antagonists are not mandatory premedications for docetaxel, some 
physicians opt to use similar premedications for docetaxel as for paclitaxel, hoping that this might reduce 
the risk of infusion reactions and other toxicities associated with docetaxel treatment. Another rationale 
for using H2 receptor antagonists is to protect the gastric mucosa against dexamethasone premedication. 
Standard doses of H2 receptor antagonists are not effective for preventing non-steroidal anti-inflammatory 
drug (NSAID)-induced gastric mucosal damage [9,24]. Whether H2 receptor antagonists are effective in 
reducing the incidence of gastric mucosal damage due to dexamethasone has not been established, and 
they are not routinely recommended unless a concurrent dose of a NSAID is prescribed. H2 receptor 
antagonists are classified as weak inhibitors of CYP3A4 activity [25]. Clinically significant drug 
interactions with H2 receptor antagonists, especially with cimetidine and chemotherapeutic agents such as 
epirubicin and 5-FU have been reported [7,8], although the contribution of CYP3A4 to the metabolism of 
epirubicin and 5-FU has not been studied extensively. It is possible that concurrent administration of H2 
receptor antagonists inhibits the CYP3A4-mediated metabolism of docetaxel, causing higher incidences 
of HFS and FE, although we do not have pharmacokinetic data to confirm this. Since H2 receptor 
antagonists such as cimetidine are likely to be co-prescribed or self-administered with anti-neoplastic 



































































Cyclophosphamide, used in the TC regimen, is inactivated by side-chain oxidation mediated by 
CYP3A4, the same enzyme involved in docetaxel metabolism [26]. This competition might be the one of 
the mechanisms involved in the increased toxicity of the TC regimen, as observed in the present study. 
However, it is difficult to explain why the TC regimen was associated with an increased frequency of FE 
but not HFS. One possible explanation is that in our analysis the high incidence of HFS in the TX 
regimen, a non-TC regimen, diminished the difference between TC and combined non-TC regimens, 
despite the very small number of patients treated using the TX regimen. An alternative explanation is that 
different mechanisms underlie the occurrence of HFS and FE. 
Our retrospective observational study suggests that concurrent use of H2 receptor antagonists with 
docetaxel-based regimens may increase the incidence of grade 2 or higher skin toxicities such as FE and 
HFS, possibly via an inhibitory effect of H2 receptor antagonists on the CYP3A4-mediated clearance of 
docetaxel. Also, the TC regimen may increase FE but not HFS. The dose of dexamethasone on days 1 and 
2 seems to play no role in skin toxicity. 
The occurrence of a specific side-effect can be used to predict the likelihood of treatment success, 
with dose-related toxicity possibly indicating an adequate concentration for efficacy. For aromatase 
inhibitors and tamoxifen, there is some evidence that women with vasomotor symptoms have a lower risk 
of recurrence than those without [27]. Co-administration of tamoxifen with the selective serotonin 



































































main active metabolite, endoxifen, possibly resulting in reduced treatment efficacy [28]. It remains 
unclear whether dexamethasone given 24 hours prior to chemotherapy reduces the severity of peripheral 
edema via the stimulation of CYP3A4 enzyme, leading to lower docetaxel exposure. Only clinical 
pharmacological studies will answer this question. However, it is certainly clear that we must always 
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Figure 1. Cumulative incidence of (A) hand-foot syndrome (HFS) and (B) facial erythema (FE) among 
patients treated with docetaxel as an adjuvant or neoadjuvant chemotherapeutic treatment for breast 
cancer (N = 993). All, all patients; H2+, patients who received an H2 blocker; H2-, patients who did not 




































































Table 1. Details of medications received by patients treated with docetaxel as an adjuvant or neoadjuvant 
chemotherapeutic treatment for breast cancer 
 
Factor Category No. of patients No. of institutions 
Total no. patients   993 (100.0%) 20 
Docetaxel dose 25 6 (0.6%) 1 
 (mg/m2) 60 10 (1.0%) 3 
  70 35 (3.5%) 1 
  75 760 (76.5%) 15 
  80 80 (8.1%) 1 
  Other 102 (10.3%) 3 
Regimen T 852 (85.8%) 20 
  TC 74 (7.5%) 11 
  TX 43 (4.3%) 8 
  TH 24 (2.4%) 6 
Medication       
     H2 Blocker - 718 (72.3%) 12 
  + 195 (19.6%) 6 
  Ranitidine 87 (8.8%) 3 
  Famotidine 73 (7.4%) 2 
  Lafutidine 35 (3.5%) 1 
  Dependent on patient 80 (8.1%) 2 
     D1 Dex (mg) 6 45 (4.5%) 1 
  8 460 (46.3%) 9 
  10 112 (11.3%) 2 
  12 197 (19.8%) 4 
  16 110 (11.1%) 3 
  20 6 (0.6%) 1 
  21 62 (6.2%) 1 
  24 1 (0.1%) 1 



































































  2 146 (14.7%) 3 
  4 158 (15.9%) 6 
  8 532 (53.6%) 8 
  16 75 (7.6%) 2 
  18 2 (0.2%) 1 
 
T, docetaxel monotherapy; TC, docetaxel + cyclophosphamide; TX, docetaxel + capecitabine; TH, 
docetaxel + trastuzumab; D1 Dex, dose of dexamethasone used on day 1; D2 Dex, dose of 



































































Table 2. Relationship between the incidence of hand-food syndrome (HFS) and facial erythema (FE) and 
institutional policies for use of H2 blockers, steroids, and chemotherapy regimens (univariate analysis) 
    Incidence  Odds ratio 95% CI P value 
HFS           
    H2 blocker - 66/718 (9.2%) Reference － － 
  + 40/195 (20.5%) 2.55 (1.66, 3.92) <0.001 
  Ranitidine 7/87 (8.1%) 0.86 (0.38, 1.95) 0.725 
  Famotidine 14/73 (19.2%) 2.34 (1.24, 4.43) 0.009 
  Lafutidine 19/35 (54.3%) 11.73 (5.76, 23.89) <0.001 
D1 steroid 
(mg/day) 
≤8 76/505 (15.0%) Reference － － 
  >8 81/488 (16.6%) 1.12 (0.80, 1.58) 0.504 
D2 steroid 
(mg/day) 
≤8 143/916 (15.6%) Reference － － 
  >8 14/77 (18.2%) 1.20 (0.66, 2.20) 0.553 
Regimen Non-TC 149/919 (16.2%) Reference   - 
  TC 8/74 (10.8%) 0.58 (0.23, 1.46) 0.245 
FE           
H2 blocker - 25/718 (3.5%) Reference － － 
  + 28/195 (14.4%) 3.00 (2.64, 8.18) <0.001 
  Ranitidine 8/87 (9.2%) 2 (1.23, 6.43) 0.015 
  Famotidine 6/73 (8.2%) 1 (0.98, 6.26) 0.054 
  Lafutidine 14/35 (40.0%) 18.48 (8.43, 40.52) <0.001 
D1 steroid 
(mg/day) 
≤8 39/505 (7.7%) Reference － － 
  >8 64/488 (13.1%) 1.80 (1.19, 2.74) 0.006 
D2 steroid 
(mg/day) 
≤8 100/916 (10.9%) Reference － － 
  >8 3/77 (10.3%) 0.33 (0.10, 1.07) 0.065 
Regimen Non-TC 91/919 (9.9%) Reference － － 




































































TC, docetaxel + cyclophosphamide; Non-TC, includes docetaxel monotherapy, docetaxel + capecitabine, 
and docetaxel + trastuzumab. D1 steroid, dose of dexamethasone used on day 1; D2 steroid, dose of 



































































Table 3. Relationship between incidence of hand-foot syndrome (HFS) and facial erythema (FE) and 
institutional policies on day 1 steroid dose, H2 blocker usage and chemotherapy regimen (multivariate 
analysis) 
Event  Factor  Usage  Odds ratio  95% CI  P value  
HFS  H2 blocker  -  Reference  －  －  
    +  2.88 (1.78, 4.67)  <0.001   
    Ranitidine 1.10 (0.46, 2.64) 0.833 
    Famotidine 2.45 (1.28, 4.67) 0.007 
     Lafutidine 14.52 (6.61, 31.89)  <0.001   
  D1 steroid (mg/day)   ≤8  Reference  －  －  
     >8  0.70  (0.43, 1.13)  0.145 
  Regimen  Non-TC  Reference  －  －  
      TC  0.77 (0.30, 1.99)  0.595 
FE  H2 blocker  -  Reference  －  －  
    +  4.09 (2.17, 7.70)  <0.001   
    Ranitidine 2.17 (0.86, 5.47) 0.101 
    Famotidine 2.92 (1.12, 7.60) 0.028 
     Lafutidine 18.75 (7.66, 45.92) <0.001   
  D1 steroid (mg/day)   ≤8  3 －  －  
     >8  2 (0.70, 3.01)  0.319 
  Regimen  Non-TC  1 －  －  
      TC  4.29 (1.89, 9.73)  <0.001 
 
TC, docetaxel + cyclophosphamide; Non-TC, includes docetaxel monotherapy, docetaxel + capecitabine, 



































































Table 4. Relationship between incidence of hand-foot syndrome (HFS) and facial erythema (FE) and 
institutional policies on day 2 steroid dose, H2 blocker usage and chemotherapy regimen (multivariate 
analysis) 
Event  Factor  Usage  Odds ratio  95% CI  P value  
HFS  H2 blocker  -  Reference  －  －  
    +  2.42 (1.56, 3.74)  <0.001   
    Ranitidine 0.91 (0.40, 2.06) 0.822 
    Famotidine 1.85 (0.91, 3.74) 0.089 
     Lafutidine 11.97 (5.84, 24.5)  <0.001   
  D2 steroid (mg/day)   ≤8  Reference  －  －  
     >8  1.74 (0.86, 3.51)  0.121 
  Regimen  Non-TC  Reference  －  －  
      TC  0.74 (0.29, 1.90)  0.528 
FE  H2 blocker  -  Reference  －  －  
    +  5.31 (2.97, 9.47)  <0.001   
    Ranitidine 2.58 (1.11, 6.01) 0.029 
    Famotidine 3.72 (1.35, 10.28) 0.011 
     Lafutidine 22.46 (9.96, 50.63) <0.001   
  D2 steroid (mg/day)   ≤8  3 －  －  
     >8  2 (0.15, 2.09)  0.392 
  Regimen  Non-TC  1 －  －  
      TC  4.42 (1.95, 10.05)  <0.001 
 
TC, docetaxel + cyclophosphamide; Non-TC, includes docetaxel monotherapy, docetaxel + capecitabine, 
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